LYRA

Lyra Therapeutics Inc. (LYRA) | Rumor.io

Lyra Therapeutics

LYRA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)398K

Net income (annual)-28.9M

Social

What share of all stock conversation is about LYRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 28

$LYRA surges 23.30% to $2.09, breaking resistance on 161K volume, with a corporate update acting as catalyst.
The stock is holding near highs, potentially leading to expansion, with a measured technical target projecting towards $2.73.
$LYRA decisively breaks $1.86 resistance, confirmed by a 24.19% move on 159.45K volume, with a next technical target at $2.77.

Generated by AI

Sentiment

Of the messages about LYRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	74.52% -3.62
Bearish	—	—	100% 0	25.48% +3.62

Bullish· Jun 4

$LYRA has surged 376% on phase 3 rhinosinusitis data, breaking its 200-day EMA and trendline resistance.
The asset is expected to reach $50 or more, with some analysts predicting a price of $40 or higher.
$LYRA's momentum continues, with some traders anticipating a pullback of only 10% before the stock hits $40.

Bearish· Jan 12

Lyra Therapeutics, Inc. has suspended development of its lead product candidate, LYR-210, for chronic rhinosinusitis, and is exploring strategic alternatives, including a potential sale.
The company's cash runway is expected to last until Q3 2026, but its remaining management is incentivized to push for a sale, which could be completed quickly.
Lyra Therapeutics' workforce has been reduced to 28 employees, and the company's equity value is negative, with a potential delisting from the stock exchange.

Generated by AI

Topics

Of the messages about LYRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.1%
Announcements	—	—	—	85.08%
Controversies	—	—	—	0%
Earnings	—	—	—	0.55%
Macro	—	—	—	0%
Technical Analysis	—	—	—	13.26%

Announcements· Apr 8

Lyra Therapeutics, Inc. will run a testnet trading competition with $50,000 in $LYRA prizes, open to Alpha program participants and select traders.
Lyra Therapeutics has announced a private placement of securities to raise $100.5 million.
$LYRA shares have surged after the company reported a private placement for gross proceeds of $100.5 million.

Technical Analysis· Jun 3

$LYRA is showing a potential cup and handle pattern on the hourly chart.
The stock has seen a pullback, but may be due for a bounce to $40 or $50, depending on the trader's strategy.
Technical indicators such as RSI and VWAP suggest that $LYRA may be overbought, and short sellers are loaded up, potentially leading to a sell-off unless margin calls hit the retail shorts.

Generated by AI

Community

Of the messages about LYRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	23.74%
Newcomers	—	—	100%	76.26%

Regulars· Apr 8

Lyra Therapeutics has secured a $100.5 million private placement at $4.22/share, providing capital for execution of trials.
The company has announced a strong private placement, and the focus can now shift back to execution of trials, with the primary endpoint in Phase 3 expected to be easily achieved.
Lyra Therapeutics' stock has surged 25.9% following the private placement, and the company has received a buy rating from Jefferies on May 26, 2020.

Newcomers· Jan 12

Lyra Therapeutics has suspended development of its lead product candidate LYR-210 for chronic rhinosinusitis, despite positive Phase 3 data, and is exploring strategic alternatives or a sale.
The company has implemented significant cost reductions, including a workforce cut affecting all remaining staff, and is still sitting on $22 million in cash and assets.
The stock has experienced a sharp decline, with some analysts seeing a potential entry point due to the strategic pivot, while others view it as a dead cat bounce waiting to be corrected.

Generated by AI

Also Discussed

Investors talking about LYRA also mention

#	Name	Attention
1	VSTA - Vasta Platform Limited	——
2	Central Securities CorporationCET	0%0
3	TD SYNNEX CorporationSNX	0%0
4	Fidelity National Information Services, Inc.FIS	0%new
5	Frax ShareFXS	0%+0
6	RadNet Inc.RDNT	0%0
7	GMXGMX	0.04%+0.02
8	Genius Group Ltd.GNS	0.37%-0.12
9	INST - Instructure Holdings, Inc.	——
10	BalancerBAL	0%0

Lyra Therapeutics Inc.

Healthcare
Biotechnology

Lyra Therapeutics Inc. is a biopharmaceutical company focusing on developing therapies for patients with ear, nose, and throat (ENT) diseases. The company's primary purpose is to address the unmet needs in the treatment of chronic rhinosinusitis (CRS) and related conditions by utilizing an innovative polymer-based platform, XTreo, which offers sustained delivery of medications directly to the affected area. This strategic approach aims to enhance treatment efficacy, reduce systemic side effects, and improve patient outcomes. Lyra's work primarily impacts the healthcare sector, particularly within the specialty pharmaceuticals industry. The significance of Lyra Therapeutics in the market lies in its potential to transform ENT disease management with novel, localized therapies that address the root cause of the ailment, positioning itself as a leader in the evolution of targeted, long-term ENT treatments.

Website

Location

480 Arsenal Way

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about LYRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 28

$LYRA surges 23.30% to $2.09, breaking resistance on 161K volume, with a corporate update acting as catalyst.
The stock is holding near highs, potentially leading to expansion, with a measured technical target projecting towards $2.73.
$LYRA decisively breaks $1.86 resistance, confirmed by a 24.19% move on 159.45K volume, with a next technical target at $2.77.

Generated by AI

Sentiment

Of the messages about LYRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	74.52% -3.62
Bearish	—	—	100% 0	25.48% +3.62

Bullish· Jun 4

$LYRA has surged 376% on phase 3 rhinosinusitis data, breaking its 200-day EMA and trendline resistance.
The asset is expected to reach $50 or more, with some analysts predicting a price of $40 or higher.
$LYRA's momentum continues, with some traders anticipating a pullback of only 10% before the stock hits $40.

Bearish· Jan 12

Lyra Therapeutics, Inc. has suspended development of its lead product candidate, LYR-210, for chronic rhinosinusitis, and is exploring strategic alternatives, including a potential sale.
The company's cash runway is expected to last until Q3 2026, but its remaining management is incentivized to push for a sale, which could be completed quickly.
Lyra Therapeutics' workforce has been reduced to 28 employees, and the company's equity value is negative, with a potential delisting from the stock exchange.

Generated by AI

Topics

Of the messages about LYRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.1%
Announcements	—	—	—	85.08%
Controversies	—	—	—	0%
Earnings	—	—	—	0.55%
Macro	—	—	—	0%
Technical Analysis	—	—	—	13.26%

Announcements· Apr 8

Lyra Therapeutics, Inc. will run a testnet trading competition with $50,000 in $LYRA prizes, open to Alpha program participants and select traders.
Lyra Therapeutics has announced a private placement of securities to raise $100.5 million.
$LYRA shares have surged after the company reported a private placement for gross proceeds of $100.5 million.

Technical Analysis· Jun 3

$LYRA is showing a potential cup and handle pattern on the hourly chart.
The stock has seen a pullback, but may be due for a bounce to $40 or $50, depending on the trader's strategy.
Technical indicators such as RSI and VWAP suggest that $LYRA may be overbought, and short sellers are loaded up, potentially leading to a sell-off unless margin calls hit the retail shorts.

Generated by AI

Community

Of the messages about LYRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	23.74%
Newcomers	—	—	100%	76.26%

Regulars· Apr 8

Lyra Therapeutics has secured a $100.5 million private placement at $4.22/share, providing capital for execution of trials.
The company has announced a strong private placement, and the focus can now shift back to execution of trials, with the primary endpoint in Phase 3 expected to be easily achieved.
Lyra Therapeutics' stock has surged 25.9% following the private placement, and the company has received a buy rating from Jefferies on May 26, 2020.

Newcomers· Jan 12

Lyra Therapeutics has suspended development of its lead product candidate LYR-210 for chronic rhinosinusitis, despite positive Phase 3 data, and is exploring strategic alternatives or a sale.
The company has implemented significant cost reductions, including a workforce cut affecting all remaining staff, and is still sitting on $22 million in cash and assets.
The stock has experienced a sharp decline, with some analysts seeing a potential entry point due to the strategic pivot, while others view it as a dead cat bounce waiting to be corrected.

Generated by AI

Lyra Therapeutics

Social

Jan 28

Sentiment

Bullish· Jun 4

Bearish· Jan 12

Topics

Announcements· Apr 8

Technical Analysis· Jun 3

Community

Regulars· Apr 8

Newcomers· Jan 12

Also Discussed

Lyra Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Jan 28

Sentiment

Bullish· Jun 4

Bearish· Jan 12

Topics

Announcements· Apr 8

Technical Analysis· Jun 3

Community

Regulars· Apr 8

Newcomers· Jan 12